BTK and B-cell chronic lymphocytic leukemia: First to third occurrence of grade 3 or 4: dose interruptions are recommendedFourth occurrence: discontinuation of BTK inhibitor is recommended (unless thrombocytopenia is related to CLL infiltration of the bone marrow)